Inhalation-type pharmaceutical composition for the treatment of hypertension and preparation method thereof

• US 9,827,193 B2
• Filed: 03/23/2015
• Issued: 11/28/2017
• Est. Priority Date: 04/18/2014
• Status: Active Grant

• Current Assignee: Hsin-Yung Lin
• Original Assignee: Hsin-Yung Lin
• Inventors: Lin, Hsin-Yung
• Primary Examiner(s): Oh, T. Victor
• Application Number:
  US14/666,069
• Publication Number:
  US 20150297515A1
• Time in Patent Office: 981 Days
• Field of Search: 514356, 514381, 514423, 514657
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 31/4418 having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention provides an inhalation-type pharmaceutical composition for hypertension and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising propranolol, captopril, amlodipine besylate, losartan, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Claims

1. An inhalation-type pharmaceutical composition for the treatment of hypertension, comprising a first gas and an atomized medicine, wherein the first gas comprises hydrogen, the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 4.7 to 96%, the atomized medicine is selected from a group consisting of propranolol, captopril, amlodipine besylate, losartan, and any combination thereof.

2. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 1, wherein the first gas further comprises oxygen.

3. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 2, wherein the first gas is a gas mixture of hydrogen and oxygen generated from electrolyzing water, where the volume ratio of hydrogen to oxygen is about 2:

1.

4. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 2, further comprising a second gas for reducing the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition, wherein the second gas is a gas selected from a group consisting of air, water vapor, inert gas, oxygen and any combination thereof.

5. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 1, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 4.7 to 66.66%.

6. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 1, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 60 to 66.66%.

7. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 1, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is larger than 66.66%.

8. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 1, wherein the atomized medicine is generated by atomizing or vaporizing a medicinal liquid.

9. The inhalation-type pharmaceutical composition for the treatment of hypertension of claim 8, wherein the medicinal liquid is selected from a group consisting of propranolol, captopril, amlodipine besylate, losartan, and any combination thereof.

10. A preparation method for an inhalation-type pharmaceutical composition for the treatment of hypertension, comprising the following steps:

(S1) preparing a first gas, wherein the first gas comprising hydrogen;

(S2) atomizing a medicinal liquid in order to generate an atomized medicine, wherein the atomized medicine is selected from a group consisting of propranolol, captopril, amlodipine besylate, losartan, and any combination thereof; and

(S3) mixing the first gas and the atomized medicine in order to generate the inhalation-type pharmaceutical composition, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 4.7 to 96%.

11. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 10, further comprising the following step after step (S2):

(S23) preparing a second gas.

12. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 11, wherein in step (S3), the inhalation-type pharmaceutical composition is generated from mixing the first gas, the second gas, and the atomized medicine.

13. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 11, wherein the second gas is used for reducing the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition.

14. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 11, wherein the second gas is a gas selected from a group consisting of air, water vapor, inert gas, oxygen and any combination thereof.

15. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 10, wherein in step (S1), the first gas is generated by electrolyzing water, the first gas comprises a gas mixture of hydrogen and oxygen, where the volume ratio of hydrogen to oxygen is 2:

1.

16. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 10, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 4.7 to 66.66%.

17. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 10, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 60 to 66.66%.

18. The preparation method for the inhalation-type pharmaceutical composition for the treatment of hypertension of claim 10, wherein the gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is larger than 66.66%.